Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Prudential Financial Inc.

Prudential Financial Inc. grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 30.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 553,424 shares of the biopharmaceutical company’s stock after purchasing an additional 128,525 shares during the quarter. Prudential Financial Inc.’s holdings in Catalyst Pharmaceuticals were worth $11,550,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at about $27,000. Farther Finance Advisors LLC raised its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 1,495 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 2,994 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $65,000. Finally, KBC Group NV grew its holdings in Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,542 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Insiders Place Their Bets

In related news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on CPRX. Bank of America reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Robert W. Baird upped their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $32.29.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX opened at $24.69 on Friday. The company has a market capitalization of $3.00 billion, a P/E ratio of 20.92, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $26.16. The company’s 50 day simple moving average is $22.66 and its 200 day simple moving average is $21.80.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.